29
/
en
AIzaSyAYiBZKx7MnpbEhh9jyipgxe19OcubqV5w
April 1, 2024
2135704
178559
2

oct 5, 2016 - FDA convened a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management to discuss naloxone products intended for use in the community, specifically the most appropriate dose or doses of naloxone to reverse the effects of life-threatening opioid overdose in all ages.

Added to timeline:

13 Nov 2018
0
0
313
Opioids and the FDA

Date:

oct 5, 2016
Now
~ 7 years and 5 months ago
PremiumAbout & FeedbackTermsPrivacy
logo
© 2022 Selected Technologies LLC – Morgan Hill, California